Oncotype DX is a genomic test used to assess the risk of breast cancer recurrence in patients. It analyzes the activity of specific genes in a tumor sample to provide a score that helps guide treatment decisions. This score can indicate whether a patient may benefit from chemotherapy after surgery. The test is particularly useful for patients with early-stage, hormone receptor-positive breast cancer. By providing insights into the tumor's biology, Oncotype DX helps doctors and patients make more informed choices about the necessity and intensity of additional treatments.